Background: The purpose of this study was to characterize the pharmacokinetics of the phosphatidylethanol (PEth) 16:0/20:4 homolog in uncoagulated human blood samples taken from 18 participants in a clinical laboratory setting after consumption of 2 standard doses of ethanol (EtOH).
P HOSPHATIDYLETHANOL (PETH) IS an abnormal cell membrane phospholipid generated only in the presence of ethanol (EtOH; Alling et al., 1983; Gustavsson and Alling, 1987; Kobayashi and Kanfer, 1987) . At normal physiological conditions, phospholipase D (PLD) hydrolyzes phosphatidylcholine (PC) into phosphatidic acid and choline, but in the presence of EtOH, PLD favors transphosphatidylation of PC into the corresponding PEth species (Kobayashi and Kanfer, 1987) . PEth is synthesized in the membranes of most types of cells in humans and animals analyzed to date (Aradottir et al., 2002) including in blood erythrocyte cell membranes (Varga et al., 2000) . While PEth is rapidly degraded in all other tissues, human red blood cells lack an enzyme (PC phospholipase) responsible for the degradation of PEth (Arad ottir et al., 2004) , and thus, its half-life in whole blood is much longer than in other tissues.
PEth has become well accepted as a direct biomarker of alcohol consumption (Aradottir et al., 2006; Beck et al., 2018; Simon, 2018; Varga et al., 1998; Walther et al., 2018) for the following reasons: First, PEth is highly specific because, as mentioned above, it is only generated in the presence of EtOH and therefore is a direct biomarker of alcohol intake. Second, PEth is highly sensitive because it is detectable after consuming alcohol equivalent to just 1 or 2 standard drinks . Third, its half-life ranges from 3 to 12 days for combined PEth (Gnann et al., 2012; Javors et al., 2016; Schr€ ock et al., 2017; Varga et al., 2000) , about 8 days for PEth 16:0/18:1 and about 6 days for PEth 16:0/18:2 (Hill- Kapturczak et al., 2018) .
Compared to other direct biomarkers of alcohol consumption, the longer PEth half-lives are more useful than the short half-lives of other biomarkers such as blood and breath (BrAC) alcohol concentrations, 2 to 3 hours; urinary ethyl glucuronide, 2 to 3 hours (Schmitt et al., 1997) ; and urinary ethyl sulfate, 2 to 4 hours (Høiseth et al., 2007 (Høiseth et al., , 2009 . When compared against indirect biomarkers, PEth has intermediate half-lives, which may better detect more recent or moderate drinking than the longer half-lives of gammaglutamyltransferase (GGT), 28 days (Orrego et al., 1985) , and carbohydrate deficient transferrin (%CDT), 15 days (Stibler, 1991) .
To date, 48 homologs of PEth have been identified (Gnann et al., 2010) . These homologs are differentiated by the number of carbons and double bonds present in their fatty acid moieties, which mirror the PC species from which they are derived. Of the 48 PEth homologs, the 2 most abundant in whole blood of alcohol drinkers are PEth 16:0/18:1 (palmitoyl/oleoyl) and PEth 16:0/18:2 (palmitoyl/linoleyl), representing 37 and 26%, respectively, of total PEth (Helander and Zheng, 2009) . A third homolog, PEth 16:0/20:4 (palmitoyl/arachidonoyl), accounts for an additional 13% of total PEth (Helander and Zheng, 2009) , making it an appealing candidate to combine with PEth 16:0/18:1 and PEth 16:0/18:2 for clinical applications.
Our previous studies characterized the pharmacokinetics of PEth 16:0/18:1 and PEth 16:0/18:2 in human blood after alcohol intake (Hill-Kapturczak et al., 2018; Javors et al., 2016) , as well as in postmortem brain and serum samples at the time of death (Thompson et al., 2016) . Other research groups have reported results that conform to our findings and form the basis of support for the use of PEth as a direct biomarker of alcohol consumption (Gnann et al., 2014; Schr€ ock et al., 2016; Ullah et al., 2017; Wang et al., 2017; Zheng et al., 2011) . Taken together, these studies indicate that PEth 16:0/18:1 and PEth 16:0/18:2 are sensitive enough to detect drinking even at the social level (<2 drinks per day) and have a wider window of detection than other biomarkers for alcohol consumption based on half-lives ranging from 4 to 12 days.
In this study, we assessed the pharmacokinetics of PEth 16:0/20:4, the third most abundant PEth homolog in human whole blood, and compared its synthesis and elimination with those of PEth 16:0/18:1 and PEth 16:0/18:2. PEth 16:0/ 20:4 in whole blood samples has the potential to provide additional pharmacokinetic information to improve estimation of alcohol consumption when measured simultaneously with PEth 16:0/18:1 and PEth 16:0/18:2.
MATERIALS AND METHODS

Participants, Study Design, Blood Collection, and BrAC Measurements
This study was performed as a substudy that was part of a larger study designed to characterize the pharmacokinetics of PEth 16:0/ 18:1 and PEth 16:0/18:2 in a laboratory setting to determine their clinical usefulness. The main study research participants, inclusionexclusion criteria, study design, blood collection, and BrAC monitoring have been described previously (Hill-Kapturczak et al., 2018) . The human experimental protocol was approved by the Institutional Review Board at The University of Texas Health Science Center at San Antonio. From the participants in the main study, only PEth 16:0/20:4 was measured in a subset of 18 participants (8 females and 10 males) for whom samples for all time points remained after finishing the main study examining PEth 16:0/18:1 and PEth 16:0/18:2 completed more than 1 year earlier (Helander and Zheng, 2009) . Participants between the ages 21 and 54 were recruited and randomly assigned to drink either 0.4 g/kg or 0.8 g/kg of alcohol in 3 equal volumes during the first 15 minutes. They were asked to abstain from drinking alcohol for 7 days before alcohol administration and wore a transdermal alcohol concentration monitor throughout the study to promote abstinence. Blood samples and BrAC were obtained at 0, 15, 30, 45, 60, 90, 120 , and 360 minutes during administration day and on the second, fourth, seventh, 11th, and 14th days during the follow-up time period, and upon collection immediately frozen in 2 sets of tubes, A and B. On the analysis day, blood samples were thawed at room temperature for a maximum of 15 minutes, and then, 2 ml of isopropanol spiked with 10 ll of the PEth 16:0/20:4-d 5 internal standard solution was added to 300 ll of each sample. The samples were vortexed for 1 minute, and then, 3 ml of hexane was added followed by shaking for 30 minutes and then centrifuged for 30 minutes at 3,2009g at 4°C. The clear supernatants were transferred to new tubes and evaporated to residues with a gentle stream of nitrogen at 30°C. The residues were dissolved in 100 ll mobile phase A (40% 2 mM ammonium acetate with 60% acetonitrile) and then transferred to microfilter tubes and centrifuged at 1,0009g for 10 minutes. These final eluted samples were transferred to 300 ll polypropylene autosampler vials and then 10 ll was injected into the HPLC/MS/ MS system.
HPLC with MS Detection
The HPLC system consisted of a Shimadzu CBM-20A communications bus module, 2 LC-20AD pumps with a DGU-20A degassing unit and mixing chamber, a SIL-20ACHT autosampler, a CTO-20AC column oven (all from Shimadzu Scientific Instruments, Inc., Houston, TX) and an AB Sciex API 4000 (AB Sciex LLC., Framingham, MA) Q-TRAP mass spectrometer with turbo ion spray (IS). The analytical column was a High Purity C4 (Thermo Fisher Scientific, Waltham, MA). Mobile phase A was 40% 2 mM ammonium acetate with 60% acetonitrile, and mobile phase B was 100% isopropanol. The solvent program was, at 1-minute 65% mobile phase A and 35% mobile phase B, at 5.0-minute 1% mobile phase A and 99% mobile phase B, at 8.0-minute 1% mobile phase A and 99% mobile phase B, and at 8.1-minute 65% mobile phase A and 35% mobile phase B, and stop time at 10 minutes.
MS parameters: electrospray ionization interface operated in negative ion mode using selected reaction monitoring to detect the major product ions from the deprotonated molecules of PEth 16:0/ 20:4 (m/z 723?303) and deuterated PEth 16:0/20:4 (m/z 728?303). The MS gas settings were CUR (curtain gas) 15 psi, CAD (collision gas) 8 psi, IS (IS voltage) À4,500 V, temperature 550°C, gas 1 (nebulizer gas) 60 psi, and gas 2 (auxiliary gas) 60 psi. The MS parameters for the PEth 16:0/20:4 analyte were DP (declustering potential) À50 V, Ep (entrance potential) À10 V, CE (collision energy) À42 V, and CXP (collision cell exit potential) À15 V. The MS parameters for the deuterated PEth 16:0/20:4-d 5 were DP À101 V, Ep À10 V, CE À40 V, and CXP À18 V. The flow rate was 350 ll/ min and the injection volume 10 ll. The ratio of peak areas of PEth 16:0/20:4 to deuterated PEth 16:0/20:4 was compared against a linear regression of ratios of calibrators from 0 to 2,000 ng/ml. Concentrations were expressed in ng/ml.
A partial validation was performed for PEth 16:0/20:4 only because PEth 16:0/18:1 and PEth 16:0/18:2 were validated previously (Hill-Kapturczak et al., 2018; Javors et al., 2016) . PEth 16:0/ 20:4 limit of detection and lower limit of quantitation were estimated to be 0.8 and 4.0 ng/ml, respectively. The upper limit of linearity was not detected at the largest calibrator concentration of 1,000 ng/ml, indicating that saturation is reached at higher concentrations. Matrix effect samples from 6 nondrinking subjects were tested, and no interference was observed. Percent recovery between extracted and unextracted samples was determined to be 90%. PEth 16:0/20:4 analytical and in internal standards were determined to be stable when using aliquots of 1 mg/ml superstock and working solutions prepared at 1 lg/ml stored at À80°C and freshly obtained in every run.
Statistical Analysis
Experimental results obtained for the baselines of the 3 homologs before alcohol administration were statistically analyzed to see whether there was any difference in levels of homolog using parametric ordinary 1-way analysis of variance (ANOVA), after testing for normality. Results for the maximum concentration (C max ), area under the curve (AUC) for the 360 minutes after alcohol dosing (AUC 360), and half-life of each of the PEth homologs at the 2 alcohol dosages were statistically analyzed for differences among doses and homologs using 2-way repeated measures ANOVA. The 2 factors were dose (between-factor) and PEth homolog (within-factor, repeated measure). Repeated measures were only established for the homolog factor because the homologs were measured in the same participant. AUC 360s were calculated for the increase in PEth levels above baseline using the trapezoid rule with Prism 7.04 software (GraphPad Software Inc., La Jolla, CA). Tukey's multiple comparison test was performed to identify which group means were significantly different. Because of the small sample size, 95% confidence intervals (CIs) were computed as well. Data are expressed as mean AE SD. Statistical analyses were performed using GraphPad Prism software, version 7.04.
RESULTS
Demographics
Of the 18 participants in this study, 8 (5 males and 3 females) individuals were from the group that consumed 0.4 g/kg of alcohol and 10 (5 males and 5 females) individuals were from the group that consumed 0.8 g/kg of alcohol. The mean age of participants in the low dose was 29 AE 7 years old (27 AE 5 for males and 31 AE 10 for females). The range age was 22 to 34 years old (22 to 34 for males and 22 to 31 for females). The mean age of participants in the high dose was 27 AE 6 years old (25 AE 4 for males and 29 AE 7 for females). The range age was 22 to 37 years old (22 to 33 for males and 22 to 37 for females). The mean weight of participants in the low dose was 79 AE 11 kg (85 AE 6 for males and 69 AE 10 for females). The range weight was 57 to 93 kg (79 to 93 for males and 57 to 77 for females). The mean weight of participants in the high dose was 72 AE 16 kg (86 AE 12 for males and 58 AE 9 for females). The range age was 47 to 100 kg (75 to 100 for males and 47 to 70 for females). In the 0.4 g/kg dose group, there were 7 whites (4 males and 3 females) and 1 participant selected to disclose his race. In this same category, there were 5 Hispanics (3 males and 2 females) and 3 non-Hispanics (2 males and 1 female). In the 0.8 g/kg dose group, there were 1 female Asian, 2 male blacks, 5 whites (1 male and 4 females), and 2 male multiracial participants. In this same category, there were 5 Hispanics (3 males and 2 females) and 5 non-Hispanics (2 males and 3 females).
Description of BrAC Measurements
Proportional increases to the 0.4 and 0.8 g/kg alcohol doses consumed were observed in all participants. Mean maximum concentration levels were reached at 45 minutes after the 0.4 g/kg initial alcohol dose, 0.0390 AE 0.007 g/dl, and at 60 minutes after the 0.8 g/kg dose, 0.0899 AE 0.016 g/ dl. The BrAC values for the doses were significantly different between doses at every time point (p < 0.0001), except at 0 and 360 minutes, in which there was no difference in BrAC concentration levels. BrAC AUCs were higher in participants that consumed 0.8 g/kg of alcohol than those that drank the 0.4 g/kg dose (21.0 AE 3.2 vs. 6.75 AE 0.6; 95% CI for the difference = 14.7 to 27.4 and 5.48 to 8.01, respectively; p < 0.0001).
Pharmacokinetics of PEth 16:0/20:4
The pharmacokinetic profiles of PEth 16:0/20:4 (Fig. 1A) , PEth 16:0/18:1 (Fig. 1B, upper panel) , and PEth 16:0/18:2 (Fig. 1B, lower The mean baseline values, before administering alcohol doses, of the 3 homologs differed significantly, F(1, 21) = 8.1; p = 0.0070. Significantly lower levels of PEth 16:0/ 20:4 were found in the 18 participants than PEth 16:0/18:1 (12 AE 9 ng/ml vs. 109 AE 98 ng/ml; 95% CI for the difference = 42 to 154; p = 0.0009) and PEth 16:0/18:2 (12 AE 9 ng/ml vs. 135 AE 189 ng/ml; 95% CI for the difference = 13 to 235; p = 0.0277), whereas the values of PEth 16:0/18:1 and PEth 16:0/18:2 were not different (109 AE 98 ng/ml vs. 135 AE 189 ng/ml; 95% CI for the difference = À47 to 99; p = 0.6398).
PEth 16:0/20:4, PEth 16:0/18:1, and PEth 16:0/18:2 levels increased to their maximum concentrations (C max ) at 45 to 90 minutes after EtOH intake. Each of the 3 homologs reached the same C max at the 2 alcohol doses, F(1, 16) = 0.15; p = 0.7075. The average increase from baseline to C max for the 3 homologs, F(2, 32) = 11; p = 0.0003, was the lowest for PEth 16:0/20:4 when compared to that of PEth 16:0/18:1 (55 AE 34 ng/ml vs. 181 AE 115 ng/ml in n = 18; 95% CI for the difference = 18 to 235; p = 0.0199) and that of PEth 16:0/18:2 (55 AE 34 ng/ml vs. 261 AE 243 ng/ml in n = 18; 95% CI for the difference = 98 to 315; p = 0.0002). There was no statistically significant difference between maximum concentrations of PEth 16:0/18:1 and PEth 16:0/18:2 (181 AE 115 ng/ml vs. 261 AE 243 ng/ml in n = 18; 95% CI for the difference = À29 to 189; p = 0.1818).
PEth 16:0/20:4, as well as PEth 16:0/18:1 and PEth 16:0/ 18:2, decreased back to baseline levels in participants that abstained from drinking during the 2-week follow-up period.
PEth 16:0/20:4 AUC 360
The overall amount of synthesis of each of the 3 PEth homologs (Fig. 2) , determined by AUC 360 for the increase above baseline levels during alcohol administration day, was approximately the same across alcohol dose, F(1, 16) = 2.1; p = 0.1686, but the levels were different among the 3 homologs, F(2, 32) = 20; p < 0.0001.
Collapsing across alcohol dose, formation of PEth 16:0/ 20:4 was significantly lower than that of PEth 16:0/18:1 (8.62 AE 5.0 lg 9 min/ml vs. 17.9 AE 11 lg 9 min/ml in n = 18; 95% CI for the difference = 2.3 to 16; p = 0.0073) and also that of PEth 16:0/18:2 (8.62 AE 5.0 lg 9 min/ml vs. 26.7 AE 14 lg 9 min/ml in n = 18; 95% CI for the difference = 11 to 25; p < 0.0001). In addition, synthesis of PEth 16:0/18:1 was lower than that of PEth 16:0/18:2 (17.9 AE 11 lg 9 min/ml vs. 26.7 AE 14 lg 9 min/ml in n = 18; 95% CI for the difference = 1.9 to 16; p = 0.0102).
PEth 16:0/20:4 Half-Life
The half-lives of PEth 16:0/20:4, PEth 16:0/18:1, and PEth 16:0/18:2 were determined over the 2-week follow-up after alcohol consumption (Fig. 3) . The half-life of the each of the 3 homologs was unaffected by alcohol dose administered, F(1, 16) = 2.1; p = 0.1673; however, the half-lives differed significantly among the homologs, F(2, 32) = 16; p < 0.0001. The elimination of PEth 16:0/20:4 was faster than that of PEth 16:0/18:1 (2.1 AE 3 days vs. 7.6 AE 3 days in n = 18; 95% CI for the difference = 3.0 to 8.2; p < 0.0001) and that of PEth 16:0/18:2 (2.1 AE 2 days vs. 6.8 AE 4 days in n = 18; 95% CI for the difference = 2.1 to 7.3; p = 0.0003). In contrast, no difference was found between the half-life of PEth 16:0/18:1 and 16:0/18:2 (7.6 AE 3 days vs. 6.8 AE 4 days in n = 18; 95% CI for the difference = À1.7 to 3.5; p = 0.6757).
DISCUSSION
The present study is the first report of the pharmacokinetics of PEth 16:0/20:4 in human blood samples in a controlled clinical laboratory study. The principal conclusions of this study are that PEth 16:0/20:4 in blood after consumption of alcohol doses of 0.4 or 0.8 g/kg (i) is synthesized at lower levels than either PEth 16:0/18:1 or PEth 16:0/18:2 and (ii) exhibits shorter half-lives than either of the other 2 homologs.
PEth 16:0/20:4 seems to peak earlier, similar to PEth 16:0/ 18:2, and there seems to be more variability in these 2 homologs compared to the PEth 16:0/18:1 homolog. There are multiple sources of variability among humans related to the synthesis of PEth homologs, including differences in PLD levels, amount of hematocrits, and rate of EtOH absorption affected by gender, percent body fat, and genetics (Hahn et al., 2016) , among other sources. These are likely the basis of the observed variability.
Only a few reports have been published that compare the pharmacokinetics of synthesis and elimination of both PEth 16:0/18:1 and PEth 16:0/18:2 (Hill- Kapturczak et al., 2018; Javors et al., 2016; Schr€ ock et al., 2016 We suggest that knowledge of the relative rates of formation and elimination of various PEth homologs might allow the estimation of recency of alcohol consumption from a single blood sample. For example, if PEth 16:0/18:1 and PEth 16:0/18:2 were present in a blood sample, but PEth 16:0/20:4 was not detectable, it would suggest that alcohol had been consumed during the past week, but not in the last couple of days. Further, if only PEth 16:0/18:1 were detectable in a blood sample, but not either of the other 2 homologs, it would suggest that alcohol consumption had not occurred within the past week or longer. Also, if the 3 homologs were detected, it would indicate that alcohol was consumed regularly up to within a couple of days. The simultaneous measurement of all 3 PEth homologs with different rates of formation and elimination should be useful to increase the accuracy of PEth as a biomarker of alcohol consumption and therefore provide a useful tool in clinical settings for screening patients for potential alcohol abuse and test treatment efficacy.
Limitations
This is a preliminary study with limitations mostly based on small sample size of 18 subjects. Nevertheless, the mean AUC 360 above baseline and the mean half-life of PEth 16:0/ 20:4 were lower than PEth 16:0/18:1 and PEth 16:0/18:2, statistically significant, and convincing differences. Differences among the PEth homologs based on alcohol dose and sex were not observed using this data set. It should be noted that these parameters were also not statistically significantly different between PEth 16:0/18:1 and PEth 16:0/18:2 in our larger study (Hill-Kapturczak et al., 2018) . Finally, PEth 16:0/ 20:4 was quantified in uncoagulated, whole blood samples (0°C) that had been thawed and refrozen a little more than 1 year earlier when testing for PEth 16:0/18:1 and PEth 16:0/ 18:2 was performed. PEth 16:0/18:1 and PEth 16:0/18:2 have been shown to be stable when stored at À80°C for several months and during freeze/thaw cycles (Helander and Zheng, 2009 ), and we can only presume the same is true for PEth 16:0/20:4. Nevertheless, even this reality indicates that PEth 16:0/20:4 is eliminated faster than the other 2 homologs and this finding would not be affected by sample stability factors.
FUTURE DIRECTIONS
One of the goals of our PEth homolog research is to evaluate the measurement of multiple isoforms in single samples to more accurately estimate the recentness and amount of recent alcohol consumption. Also, we intend to evaluate the possible combined utility of adding direct biomarkers such as ethyl glucuronide in urine or serum CDT and GGT levels to allow a more accurate assessment of recent alcohol consumption and its toxic effects. These biomarkers individually reflect different levels, time frames of consumption, and possible more serious toxic effects of alcohol use.
